In episode 136 we speak to Dentons European head of hashish, Peter Homberg, based mostly out of Berlin, in regards to the laws lately handed within the Bundestag.

Homberg explains what he calls the primary pillar of focused laws

A) Private use
B) Associations of dwelling cultivation and/or hashish

From Peter we be taught the main points, what you may and can’t do and the place there are gaps and questions within the laws, in addition to the customarily hidden downside, what position do the German federal states play within the course of and ratify / come to an settlement on to the beginning date of April 1, 2024.

Peter additionally outlines the following steps, pillar two, within the legislative course of in our dialog.

We additionally focus on what this implies for the EU as a wider physique, now that Germany has taken these steps.

Even what different jurisdictions are crossing their fingers in deciding on regulated hashish.

If you wish to know precisely what occurred in Germany this previous week relating to legalized hashish, this dialog offers you the data and context you want.

Peter Homberg

Peter Homberg is a associate within the Dentons Berlin workplace. He focuses on life sciences, IP, company regulation and M&A transactions within the life sciences and high-tech sector, in addition to R&D and cooperation agreements, cross-border IP licenses and IP methods. As well as, he has in depth expertise offering authorized recommendation on compliance points. As well as, he’s the pinnacle of the group of the European sector of Hashish. Peter inter alia advises firms within the pharmaceutical, diagnostics, biotechnology, medical machine and medical hashish industries – from startups to massive publicly traded firms. As well as, he has in depth transactional expertise in Southeast Asia. Peter is a member of the Licensing Government Society (LES), the German Affiliation for Mental Property and Copyright (GRUR), the German Arbitration Establishment (DIS) in addition to the Pharma-Lizenz-Membership Deutschland eV. conferences. He’s the creator of quite a few skilled articles and different publications associated to company regulation or IP within the area of life sciences.


  • DEMECAN GmbH: Preparation of a authorized opinion on the compatibility of the legalization of hashish for leisure functions in Germany with worldwide and European regulation. Identification of doable options to beat obstacles beneath worldwide and European regulation.
  • Cover Progress Corp.: Suggested a subsidiary of one of many main Canadian suppliers of medical hashish on the acquisition of the German inhaler producer Storz & Bickel GmbH & Co. KG for 135 million euros.
  • DEMECAN GmbH: Preparation of a complete authorized opinion relating to authorized obstacles to the legalization of hashish for leisure functions and evaluation of doable authorized options.
  • Proteona Pte. Ltd.: Advising the biotechnology firm on an unique worldwide license settlement with the Nationwide College of Singapore (NUS).
  • Canadian provider of medical hashish: Recommendation on the conclusion of a three way partnership settlement with a German pharmaceutical wholesaler.
  • Scil Know-how GmbH: Recommendation relating to the out-licensing of sure mental property for the regenerative therapy of osteoarthritis inter alia to Sanofi.
  • Scil Know-how GmbH: Suggested relating to the sale of its service and manufacturing division to Nanohale AG.
  • German biotechnology firm: Recommendation relating to the sale of a sure IP-portfolio for the therapy of coronary heart failure.
  • Mid-sized German pharmaceutical firm: Counsel relating to the licensing and distribution of a sure API for the therapy of interstitial cystitis to a multinational pharmaceutical firm in the USA.
  • US based mostly pharmaceutical firm: Recommendation relating to due diligence in reference to a sure know-how portfolio for vaccine manufacturing previous to in-licensing the know-how.
  • Biotechnology firm based mostly in Switzerland: Recommendation relating to cooperation with a French multinational pharmaceutical firm.
  • Priaxon AG: Recommendation relating to the out-licensing of sure know-how to Boehringer Ingelheim.
  • German-Singaporean biotech firm: Recommendation relating to the in-licensing of sure diagnostic know-how by the Nationwide College of Singapore.
  • French enterprise capital fund: Suggested relating to the acquisition of shares in a biotechnology firm based mostly in Germany.
  • Mid-sized German pharmaceutical firm: Recommendation relating to the restructuring of its distribution channels in Portugal and different European nations.
  • Numerous shoppers within the life sciences sector: Advising on all varieties of transactions, together with know-how switch agreements, R&D agreements, M&A transactions, personal fairness transactions, arbitration proceedings and litigation.


Peter Homberg is highlighted by Chambers Europe2014 as “an excellent negotiator”, who “has nice expertise with biotech firms and is actually aim pushed. He understands our wants very nicely”. JUVE Handbook German Enterprise Regulation Research, 2015/2016 mentions Peter Homberg as a extremely really helpful practitioner. The worldwide listing The very best legal professionals ranked him among the many greatest legal professionals for Healthcare Regulation and Pharmaceutical Regulation in Germany. World Regulation Specialists (2015, 2016, 2017, 2018), Authorized 100 (2021, 2022, 2023) and Leaders in Regulation (2020,2021) honor Peter Homberg as “Life Sciences Lawyer of the Yr in Germany”.



  • FOCUS on-lineProfessional collection on hashish regulation with common contributions, from April 2023
  • “CBD Oils: Meals or Pharmaceutical?”Authorized Trade Critiques Germany Vol. 3December 2023
  • “Present Developments within the German Legalization Course of”, Hashish Regulation JournalNovember 2023
  • “Legalization in Germany: Official Draft Regulation Launched”, Hashish Regulation JournalSeptember 2023
  • “German Hashish Regulation Undertaking – Penalties for Medical Hashish”,Authorized Trade Critiques Germany Vol. 2September 2023
  • “Latest Developments within the German Legalization Course of for Leisure Hashish”,Authorized Trade Critiques Germany Vol. 1Could 2023
  • “Marketability of CBD merchandise in Germany and the European Union”, Hashish Regulation JournalDecember 2022
  • “Basic Modifications in Future Medical Hashish Prescribing Practices”, krautinvestDecember 2022
  • “Key Proposals Doc: New Particulars on Germany's Deliberate Hashish Legalization”, Hashish Regulation JournalNovember 2022
  • “Deliberate legalization of hashish – between need and authorized actuality”, LTOSeptember 2022
  • “The destiny of the German medical hashish business post-legalization”, Hashish Regulation JournalAugust 2022
  • “On-line Hashish Commerce: The Distribution Channel of the Future?” krautinvestJuly 2022
  • “Legalization in Europe? – Candidates for the legalization of leisure hashish within the close to future,” Hashish Regulation JournalCould 2022
  • “Why the legalization of leisure hashish is questionable in worldwide regulation”, krautinvestApril 2022
  • “Legalizing leisure hashish in battle with the 1961 UN Single Conference on Narcotic Medication”, Hashish regulation reportDecember 2021
  • “Harmonization of the authorized framework for medical hashish at EU stage”, krautinvestNovember 2021
  • Co-author, “The duty to offer insurance coverage in accordance with Part 94 AMG for irradiated hashish flowers”,Pharmaceutical regulation 09/2021
  • “Synthetic Intelligence beneath the EU Medical Units Regulation”,Science4 Life2021
  • “New developments within the German marketplace for medical hashish and cannabidiol (CBD) 2021 – an outline”,Going Public, Biotechnology2021

Contact Peter

Source link